Guided by human genetics, proprietary bioinformatics and pharmacology we are deploying GPR35 antagonism as a differentiated approach to treatment of disease
We are a group of GPR35 and drug discovery specialists applying our knowledge to develop small molecule antagonists of the GPCR GPR35 for the treatment of serious digestive system disorders with high unmet clinical need
Established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs
